Stagezero Life Sciences (SZLSF) Stock Price, News & Analysis

Company Overview

StageZero Life Sciences Ltd is a molecular diagnostics company focused on the early detection of multiple cancers through non-invasive blood tests. The company leverages proprietary biomarker panels that integrate genomic and proteomic signals to identify cancer at its earliest stages. By offering a single-tube assay, StageZero aims to streamline cancer screening and improve patient outcomes through timely diagnosis and treatment.

The company’s flagship product, known as the Polaris multi-cancer early detection test, combines DNA methylation markers with protein analytes to screen for a broad spectrum of solid tumors. Polaris is currently used in clinical studies and select commercial settings across North America, with ongoing efforts to secure broader regulatory clearances. StageZero collaborates with research institutions, hospitals and laboratory partners to validate its technology and expand its testing capabilities into new cancer types and geographies.

Headquartered in Canada, StageZero Life Sciences operates laboratories and development facilities in both Canada and the United States, and is exploring strategic partnerships to extend its reach into Europe and Asia. The company is led by a management team with extensive experience in biotechnology, diagnostics and healthcare commercialization. StageZero continues to invest in research and development aimed at enhancing assay performance, scaling laboratory operations and establishing reimbursement pathways for multi-cancer screening solutions.

Key Stats

• Today's Range: $0.0051 to $0.0051
• 50-Day Range: $0.0051 to $0.0051
• 52-Week Range: $0.00 to $0.07
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: $630.11 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 7/02/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:SZLSF
• CIK: 1454263
• Web: www.stagezerolifesciences.com
• Phone: (855) 420-7140
• Fax: 905-209-2031
• Employees: 80
• Year Founded: 1998

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 123,550,000
• Free Float: 120,415,000
• Market Cap: $630.11 thousand
• Optionable: Not Optionable
• Beta: -4.20